Lineage Cell Therapeutics
LCTX
LCTX
102 hedge funds and large institutions have $140M invested in Lineage Cell Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
6% less funds holding
Funds holding: 109 → 102 (-7)
7% less capital invested
Capital invested by funds: $151M → $140M (-$11.3M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Holders
102
Holding in Top 10
2
Calls
$203K
Puts
$212K
Top Buyers
| 1 | +$1.54M | |
| 2 | +$751K | |
| 3 | +$680K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$630K |
| 5 |
BC
Broadwood Capital
New York
|
+$454K |
Top Sellers
| 1 | -$762K | |
| 2 | -$164K | |
| 3 | -$157K | |
| 4 |
Millennium Management
New York
|
-$152K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$116K |